13402-97-6Relevant articles and documents
Effective removal of calcium and magnesium sulfates from wastewater in the rare earth industry
Wang, Yanliang,Guo, Xiangguang,Bai, Yan,Sun, Xiaoqi
, p. 33922 - 33930 (2019)
The wastewater discharged from the rare earth (RE) industry generally contains a high level of calcium and magnesium sulfates, which confers permanent hardness and causes difficulties in recycling this wastewater. In this study, the alkyl phenoxy acetic acid derivatives including 4-methyl phenoxy acetic acid (M-POAA), 4-tert-butyl phenoxy acetic acid (B-POAA) and 4-tert-octyl phenoxy acetic acid (O-POAA), were synthesized via the Williamson reaction and characterized by nuclear magnetic resonance (NMR), infrared (IR), and ultra-violet (UV) spectroscopy, as well as elemental analysis and X-ray diffraction (XRD). Synthesis of the POAAs were simple and green, and the raw materials used for their production are widely available and low-cost. The potential for removal of Ca and Mg sulfates from industrial wastewater using POAAs as the organic precipitants was assessed. The total precipitation efficiencies of Ca and Mg from wastewater with the use of POAAs increased with the following order: M-POAA -1, respectively. The O-POAA could be regenerated five times without any significant change in its structure and precipitation performance. Thus, the use of the novel precipitants is a prospective alternative to the conventional processes for softening wastewater.
Identification of metabolites from the biological transformation of the nonionic surfactant residue octylphenoxyacetic acid and its brominated analog
Fujita, Yoshiko,Reinhard, Martin
, p. 1518 - 1524 (1997)
The aerobic biological transformation of octylphenoxyacetic acid (OP1EC) and its brominated analog (BrOP1EC) by groundwater enrichment cultures was studied, and persistent metabolites were identified by GC/MS. OP1EC is a representative of the class of alkylphenol ethoxycarboxylates (APEC), formed from alkylphenol polyethoxylate nonionic surfactants during sewage treatment. BrOP1EC is a byproduct formed during chlorine disinfection in the presence of bromide. The metabolite 2,4,4-trimethyl-2-pentanol was detected in stoichiometric quantities in OP1EC-metabolizing enrichment cultures, representing the intact alkyl side chain as a tertiary alcohol. BrOP1EC was transformed by the OP1EC-utilizing cultures only if OP1EC was simultaneously metabolized, suggesting a cometabolic mechanism of transformation. Brominated intermediates were also detected: brominated octylphenol and e compound tentatively identified as 2-aminomethoxy-3-bromo-5-(1,1,3,3- tetramethylbutyl)phenol.
Methyl 3-(3-(4-(2,4,4-Trimethylpentan-2-yl)phenoxy)-propanamido)benzoate as a Novel and Dual Malate Dehydrogenase (MDH) 1/2 Inhibitor Targeting Cancer Metabolism
Naik, Ravi,Ban, Hyun Seung,Jang, Kyusic,Kim, Inhyub,Xu, Xuezhen,Harmalkar, Dipesh,Shin, Seong-Ah,Kim, Minkyoung,Kim, Bo-Kyung,Park, Jaehyung,Ku, Bonsu,Oh, Sujin,Won, Misun,Lee, Kyeong
, p. 8631 - 8646 (2017/11/03)
Previously, we reported a hypoxia-inducible factor (HIF)-1 inhibitor LW6 containing an (aryloxyacetylamino)benzoic acid moiety inhibits malate dehydrogenase 2 (MDH2) using a chemical biology approach. Structure-activity relationship studies on a series of (aryloxyacetylamino)benzoic acids identified selective MDH1, MDH2, and dual inhibitors, which were used to study the relationship between MDH enzyme activity and HIF-1 inhibition. We hypothesized that dual inhibition of MDH1 and MDH2 might be a powerful approach to target cancer metabolism and selected methyl-3-(3-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)propanamido)-benzoate (16c) as the most potent dual inhibitor. Kinetic studies revealed that compound 16c competitively inhibited MDH1 and MDH2. Compound 16c inhibited mitochondrial respiration and hypoxia-induced HIF-1α accumulation. In xenograft assays using HCT116 cells, compound 16c demonstrated significant in vivo antitumor efficacy. This finding provides concrete evidence that inhibition of both MDH1 and MDH2 may provide a valuable platform for developing novel therapeutics that target cancer metabolism and tumor growth.
